Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 6.78 as of 2026-09-19T00:16:05.757Z.
Consensus retrieved: 2026-09-10T03:55:42.083Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-19T00:16:05.757Z.
Quote observation: 2026-09-18T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 28c109353c75d8b12db6c684d1955bfcc91a189e8f042ac4261563e744a70cce
Forward PE Ratio (6.78) = Dated Quote Price ($16.95) / Consensus Forward EPS ($2.50)
FORWARD PE RATIO
6.78
SECTOR MEDIAN · HEALTHCARE
18.84
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-64.02%
vs the sector median at left
Viatris Inc.
Market Cap
$19.74B
Forward PE Ratio
6.78
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Viatris Inc. (VTRS) | $19.74B | 6.78 |
| STERIS plc (STE)vs › | $19.98B | 18.30 |
| United Therapeutics Corporation (UTHR)vs › | $21.00B | 18.92 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.45B | 11.18 |
| Medpace Holdings, Inc. (MEDP)vs › | $17.09B | 34.79 |
| Revvity, Inc. (RVTY)vs › | $16.00B | 26.79 |
| Solventum Corporation (SOLV)vs › | $15.38B | 12.41 |
| BioNTech SE (BNTX)vs › | $24.13B | N/A |
| Exelixis, Inc. (EXEL)vs › | $14.67B | 16.61 |
| Incyte Corporation (INCY)vs › | $25.40B | 33.31 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
6.8
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $16.95, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.50 | $2.47 – $2.53 | 5 | 6.8x |
| 2027-12-31 | $2.66 | $2.60 – $2.75 | 5 | 6.4x |
| 2028-12-31 | $2.90 | $1.83 – $3.98 | 2 | 5.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
